SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. 

The group generates a revenue of 1.4 MM€ and operates 24 manufacturing plants and 10 R&D centers in Europe, North America and Asia. 3,400 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers.

SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.


Pharmaceutical

SEQENS

Pierre Luzeau

Delphine Blino

Véronique Fromont

Kathleen Reversé

Charlie S.

Emmanuelle Morandi

Vincent Milhau

Julien Boutet

Jean-Louis Martin

Victor Z.

Robert Monti

Alexandre Gultzgoff

Cedric Ducros

Description